Free Trial

OPKO Health Q4 2022 Earnings Report

OPKO Health logo
$1.48 +0.02 (+1.02%)
As of 03:50 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

OPKO Health EPS Results

Actual EPS
-$0.11
Consensus EPS
-$0.11
Beat/Miss
Met Expectations
One Year Ago EPS
-$0.11

OPKO Health Revenue Results

Actual Revenue
$185.40 million
Expected Revenue
$168.21 million
Beat/Miss
Beat by +$17.19 million
YoY Revenue Growth
-53.80%

OPKO Health Announcement Details

Quarter
Q4 2022
Time
After Market Closes

Conference Call Resources

Conference Call Audio

OPKO Health Earnings Headlines

Do this Before Elon’s Reveal on January 29th
Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.
See More OPKO Health Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like OPKO Health? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OPKO Health and other key companies, straight to your email.

About OPKO Health

OPKO Health (NASDAQ:OPK), a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

View OPKO Health Profile

More Earnings Resources from MarketBeat